Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Free Cash Flow (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Free Cash Flow data on record, last reported at -$9.6 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 51.34% year-over-year to -$9.6 million; the TTM value through Sep 2025 reached -$32.2 million, down 45.62%, while the annual FY2024 figure was -$25.4 million, 6.07% down from the prior year.
  • Free Cash Flow reached -$9.6 million in Q3 2025 per CRVS's latest filing, down from -$5.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$5.2 million in Q1 2024 and bottomed at -$9.6 million in Q3 2025.
  • Average Free Cash Flow over 4 years is -$6.7 million, with a median of -$6.3 million recorded in 2024.
  • The widest YoY moves for Free Cash Flow: up 36.69% in 2024, down 63.83% in 2024.
  • A 4-year view of Free Cash Flow shows it stood at -$7.5 million in 2022, then surged by 31.54% to -$5.2 million in 2023, then plummeted by 63.83% to -$8.5 million in 2024, then fell by 13.01% to -$9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$9.6 million in Q3 2025, -$5.9 million in Q2 2025, and -$8.3 million in Q1 2025.